Squarepoint
APGE

Squarepoint’s Apogee Therapeutics APGE Stock Holding History

Squarepoint’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$38.6M Buy
290,713
+252,365
+658% +$22.7M 0.04% 423
2026
Q1 		$3.23M Buy
+38,348
New +$2.78M ﹤0.01% 1830
2025
Q2 		– Sell
-16,232
Closed -$606K – 4460
2025
Q1 		$606K Sell
16,232
-20,112
-55% -$778K ﹤0.01% 3119
2024
Q4 		$1.65M Buy
36,344
+17,301
+91% +$882K ﹤0.01% 2594
2024
Q3 		$1.12M Sell
19,043
-24,979
-57% -$1.2M ﹤0.01% 2519
2024
Q2 		$1.73M Buy
44,022
+25,829
+142% +$1.25M ﹤0.01% 2156
2024
Q1 		$1.21M Buy
+18,193
New +$794K ﹤0.01% 2452

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Squarepoint's APGE Position: Q2 2026 in Review

Squarepoint increased its Apogee Therapeutics (APGE) stake by 658% in Q2 2026, buying an estimated $22.7M and bringing the position to 290,713 shares worth $38.6M. The position accounts for 0.04% of the portfolio, ranked #423.

Squarepoint first reported a position in APGE in Q1 2024 and has held it in 7 quarters since. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Squarepoint held 290,713 shares of Apogee Therapeutics worth $38.6M as of Q2 2026.
  • Squarepoint bought 252,365 Apogee Therapeutics shares in Q2 2026, an estimated $22.7M.
  • Apogee Therapeutics made up 0.04% of Squarepoint's portfolio in Q2 2026, its #423 holding.
  • Squarepoint first reported a position in Apogee Therapeutics in Q1 2024 and has held it in 7 quarters since.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.